Cuprina Holdings (Cayman) Business Summary

Cuprina Holdings (Cayman) LTD (CUPR) is a biomedical firm that generates revenue primarily through the manufacture and distribution of MEDIFLY, a proprietary line of sterile, medical-grade blowfly larvae used for Maggot Debridement Therapy (MDT) in chronic wound management. The company’s business model is built on a multi-segment strategy that includes MDT products, cosmeceuticals, and a developing amphibian collagen platform, with 2026 expansion plans into medical waste recycling and in-vitro fertilization (IVF) media production. Revenue is driven by hospital adoption and clinical sales, particularly in the Middle East and Southeast Asia, where the company is scaling its specialized bio-dressing technology. Cuprina competes with biopharmaceutical and wound care players such as Atara Biotherapeutics, Celularity, and NEXGEL, positioning itself as a niche leader in biological debridement transitioning toward a diversified biotechnology and environmental health portfolio. The company was founded by Carl Marc Baptista, a specialist in medical device commercialization who serves as Chief Technology Officer and Director. Leadership is spearheaded by CEO Yong Qi (David) Quek, whose pedigree includes executive roles at SGX-listed ABR Holdings and OEL Holdings, where he led medical device portfolio expansion and regional sales. The executive team is further strengthened by CFO Tat Jing (Jey) Chan, a veteran of Ernst & Young, and Head of R&D Dr. Naresh Waran, a former senior regulatory specialist at the Singapore Health Sciences Authority (HSA). Notable board members include Teo Peng Kwang, an executive director at Centurion Corporation, and the company recently enhanced its scientific leadership by appointing Dr. Ronald Sherman, a pioneer in medicinal maggot therapy, as Medical and Scientific Director in late 2025 to spearhead U.S. market entry.